Εξειδίκευση τύπου :	Άρθρο σε επιστημονικό περιοδικό
Τίτλος:	The thin red line between the immune system and cancer evolution
Δημιουργός/Συγγραφέας:	Baxevanis, Constantin N Goulielmaki, Maria Adamaki, Maria Fortis, Sotirios P
Ημερομηνία:	2023-01
Γλώσσα:	Αγγλικά
ISSN:	1936-5233
DOI:	10.1016/j.tranon.2022.101555
Άλλο:	36265329
Περίληψη:	The cancer immunoediting theory describes the dual ability of endogenous antitumor immunity to inhibit or promote progressing cancers. Tumor-specific neoantigens arising from somatic mutations serve as targets for the endogenous T-cell-mediated antitumor immunity and therefore possess a crucial role for tumor development. Additionally, targeting these molecules is conceptually appealing because neoantigens are not expressed in healthy tissue and therefore confer less toxicity and greater specificity when used in therapeutic interventions. Moreover, intratumor neo-antigenic heterogeneity is believed to play a pivotal role in the activation of adaptive immunity and in the efficacy of immunotherapies that are based on immune checkpoint inhibition. In this respect, mutual interactions between tumor cells and immune lymphocytes regulate the levels of antitumor immunity, but also shape tumor heterogeneity through the selective outgrowth of tumor subclones. Therefore, the exploration of the mechanistic pathways and the identification of the genomic aberrations underlying the clonal evolution of tumors is considered mandatory for improving the clinical outcomes of therapies, as it will assist in the selection of the appropriate therapeutic decisions so as to delay, avoid, or overcome resistance through the identification of the most effective therapeutic strategies.
Τίτλος πηγής δημοσίευσης:	Translational oncology
Τόμος/Κεφάλαιο:	27
Θεματική Κατηγορία:	[EL] Νεοπλάσματα. Όγκοι. Ογκολογία (περ. Καρκίνος, κακινογόνες ουσίες)[EN] Neoplasms. Tumors. Oncology (Incl.cancer, carcinogens) [EL] Κυτταρολογία[EN] Cytology [EL] Βιοχημεία[EN] Biochemistry [EL] Ανοσολογία[EN] Immunology
Λέξεις-Κλειδιά:	Immune resistance Immunoediting Immunotherapy Neoantigens Tumor heterogeneity
EU Grant identifier:	T2EDK-02218
Κάτοχος πνευματικών δικαιωμάτων:	© 2022 Published by Elsevier Inc.
Όροι και προϋποθέσεις δικαιωμάτων:	This is an open access article under the CC BY-NC-ND license.
Ηλεκτρονική διεύθυνση στον εκδότη (link):	https://www.sciencedirect.com/science/article/pii/S1936523322002145?via%3Dihub#sec0010
Εμφανίζεται στις συλλογές:	Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο